Study identifier:D9970C00001
ClinicalTrials.gov identifier:NCT06130553
EudraCT identifier:N/A
CTIS identifier:2023-506757-38
PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours That are MTAP Deficient
Advanced solid Tumours that are MTAP deficient
Phase 1/2
No
AZD3470
All
210
Interventional
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD3470 Monotherapy Part A dose escalation and DDI and Part B dose optimisation and expansion in varying doses of AZD3470 | - |